The FDA has issued draft guidance on its proposal to reclassify blood-access systems used during hemodialysis from Class III to the lower-risk Class II category. The agency cited sufficient efficacy and safety data to warrant the devices' reclassification. The guidance is up for comment through Aug. 27.

Related Summaries